Psilocybin
Other ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Psilocybin is not supported by NutriStack. Safety information only.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Psilocybin is an other. NutriStack rates the overall evidence as insufficient. This profile indexes 15 sources.
The bottom line
Evidence rating insufficient. 15 sources indexed (2013–2025), with 0 interaction records on file.
Dosing & protocol.
What it actually costs.
Real-world pricing across three quality tiers. Assumes Not recommended / controlled substance.
No effective supplement dose exists. Cost is intentionally not modeled for this illegal non-medical substance. Updated 2026-05-28.
The same dose, as food.
How much you'd eat to match a supplemental dose.
Psilocybin is a psychoactive compound, not a nutrient or diet-replaceable supplement.
Full safety detail.
Side effects
- Anxiety or panic
- Nausea
- Transient hypertension or tachycardia
- Accidents during intoxication
- Possible worsening of psychosis or mania in susceptible users
- Distressing perceptual experiences
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
12- 1Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trialsPMIDSwieczkowski D, Kwaśny A, Pruc M et al. · Psychiatry research · 2025
Swieczkowski D, Kwaśny A, Pruc M et al.. Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials. Psychiatry research. 2025
- 2Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-AnalysisPMIDMenon V, Ramamurthy P, Venu S et al. · Acta psychiatrica Scandinavica · 2025
Menon V, Ramamurthy P, Venu S et al.. Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis. Acta psychiatrica Scandinavica. 2025
- 3Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic reviewPMIDMeshkat S, Malik G, Zeifman RJ et al. · Neuroscience and biobehavioral reviews · 2025
Meshkat S, Malik G, Zeifman RJ et al.. Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neuroscience and biobehavioral reviews. 2025
- 4Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTsPMIDBorgogna NC, Owen T, Petrovitch D et al. · Psychopharmacology · 2025
Borgogna NC, Owen T, Petrovitch D et al.. Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. Psychopharmacology. 2025
- 5Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-AnalysisPMIDYerubandi A, Thomas JE, Bhuiya NMMA et al. · JAMA network open · 2024
Yerubandi A, Thomas JE, Bhuiya NMMA et al.. Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA network open. 2024
- 6Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysisPMIDHsu TW, Tsai CK, Kao YC et al. · BMJ (Clinical research ed.) · 2024
Hsu TW, Tsai CK, Kao YC et al.. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. BMJ (Clinical research ed.). 2024
- 7Therapeutic effect of psilocybin in addiction: A systematic reviewPMIDvan der Meer PB, Fuentes JJ, Kaptein AA et al. · Frontiers in psychiatry · 2023
van der Meer PB, Fuentes JJ, Kaptein AA et al.. Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in psychiatry. 2023
- 8Psychotherapy with Psilocybin for Depression: Systematic ReviewPMIDDawood Hristova JJ, Pérez-Jover V · Behavioral sciences (Basel, Switzerland) · 2023
Dawood Hristova JJ, Pérez-Jover V. Psychotherapy with Psilocybin for Depression: Systematic Review. Behavioral sciences (Basel, Switzerland). 2023
- 9Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studiesPMIDPerez N, Langlest F, Mallet L et al. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2023
Perez N, Langlest F, Mallet L et al.. Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2023
- 10Psilocybin-assisted therapy for depression: A systematic review and meta-analysisPMIDHaikazian S, Chen-Li DCJ, Johnson DE et al. · Psychiatry research · 2023
Haikazian S, Chen-Li DCJ, Johnson DE et al.. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research. 2023
- 11The therapeutic potential of psilocybin: a systematic reviewPMIDvan Amsterdam J, van den Brink W · Expert opinion on drug safety · 2022
van Amsterdam J, van den Brink W. The therapeutic potential of psilocybin: a systematic review. Expert opinion on drug safety. 2022
- 12Potential Therapeutic Effects of Psilocybin: A Systematic ReviewPMIDGoel DB, Zilate S · Cureus · 2022
Goel DB, Zilate S. Potential Therapeutic Effects of Psilocybin: A Systematic Review. Cureus. 2022
Randomized controlled trials
2- 13Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.PMIDGoodwin GM et al. · N Engl J Med · 2022
Phase 2 trial found a 25 mg supervised dose reduced depression scores more than control over 3 weeks, but headache, nausea, dizziness, and suicidality-related events were observed across groups.
- 14Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations.PMIDKometer M et al. · J Neurosci · 2013
Human study found that blocking 5-HT2A receptors attenuated psilocybin-related changes in visual processing and hallucination-like effects.
Reviews & position papers
1- 15The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.PMIDJohnson MW et al. · Neuropharmacology · 2018
Review concluded psilocybin has limited reinforcing effects but can still lead to dangerous behavior and worsening of mental illness in unprepared or unsupervised users.
Common questions.
Quick answers about Psilocybin, drawn from the data on this page.
What is Psilocybin?
Psilocybin is not supported by NutriStack. Safety information only.
What are the side effects of Psilocybin?
Reported side effects include anxiety or panic, nausea, transient hypertension or tachycardia, accidents during intoxication, possible worsening of psychosis or mania in susceptible users, distressing perceptual experiences. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Psilocybin?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Psilocybin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.